Prograf The active ingredient of the drug (Tacrolimus) binds to cytosolic protein (FKBP12), responsible for the intracellular accumulation of the drug. Designed for the prevention and treatment of allograft liver, kidneys and heart rejection reactions, including those resistant to standard immunosuppressive therapy regimes.
